Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Central Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan.
J Gastrointest Surg. 2009 Nov;13(11):1921-8. doi: 10.1007/s11605-009-0998-0. Epub 2009 Sep 2.
Hepatocellular carcinoma (HCC) with major portal tumor thrombus has been considered to be a fatal disease. A thrombectomy remains the only therapeutic option that offer a chance of complete tumor removal avoiding acute portal vein obstruction. However, the efficacy of tumor thrombectomy in addition to hepatectomy has not been well evaluated.
Of 979 patients who consecutively underwent initial HCC resection, 45 (4.6%) HCC patients with tumor invasion of the first branch of the portal vein (vp3) and tumor in the main portal trunk or the opposite-side portal branch (vp4) were retrospectively analyzed to evaluate the efficacy of hepatectomy and tumor thrombectomy.
Alpha-fetoprotein, serosal invasion, and intrahepatic metastases were independently significant prognostic factors in all the 45 patients with vp3 or vp4 HCC. The 3- and 5-year survival rates in vp3 and vp4 group were 35.3% and 41.8%, and 21.2% and 20.9%, respectively. There were longer operative times and more intraoperative bleeding in patients with vp4, but no significant difference in mortality, morbidity, and survival between patients with vp3 and vp4.
Hepatectomy and thrombectomy for vp4 could not only avoid acute portal occlusion due to tumor thrombus but provide a comparable survival benefit with hepatectomy for vp3.
肝细胞癌(HCC)伴大门静脉癌栓已被认为是一种致命疾病。血栓切除术仍然是唯一的治疗选择,它提供了完全切除肿瘤的机会,避免了急性门静脉阻塞。然而,除了肝切除术之外,肿瘤血栓切除术的疗效尚未得到很好的评估。
在连续接受初始 HCC 切除的 979 名患者中,回顾性分析了 45 名 HCC 患者(4.6%)的肿瘤侵犯门静脉第一支(vp3)和主门静脉干或对侧门静脉分支(vp4)的肿瘤,以评估肝切除术和肿瘤血栓切除术的疗效。
甲胎蛋白、浆膜侵犯和肝内转移是所有 vp3 或 vp4 HCC 患者的独立显著预后因素。vp3 和 vp4 组的 3 年和 5 年生存率分别为 35.3%和 41.8%,21.2%和 20.9%。vp4 患者的手术时间更长,术中出血更多,但 vp3 和 vp4 患者的死亡率、发病率和生存率无显著差异。
vp4 的肝切除术和血栓切除术不仅可以避免因肿瘤血栓引起的急性门静脉闭塞,而且还可以为 vp3 的肝切除术提供可比的生存获益。